keyword
MENU ▼
Read by QxMD icon Read
search

Allogenic stem cell transplant

keyword
https://www.readbyqxmd.com/read/29923253/comparison-of-survival-outcome-between-donor-types-or-stem-cell-sources-for-childhood-acute-myeloid-leukemia-after-allogenic-hematopoietic-stem-cell-transplantation-a-multicenter-retrospective-study-of-study-alliance-of-yeungnam-pediatric-hematology-oncology
#1
Ye Jee Shim, Jae Min Lee, Heung Sik Kim, Nani Jung, Young Tak Lim, Eu Jeen Yang, Jeong Ok Hah, Young-Ho Lee, Hee Won Chueh, Jae Young Lim, Eun Sil Park, Jeong A Park, Ji Kyoung Park, Sang Kyu Park
We compared transplant outcomes between donor types and stem cell sources for childhood acute myeloid leukemia (AML). The medical records of children with AML in the Yeungnam region of Korea from January 2000 to June 2017 were reviewed. In all, 76 children with AML (male-to-female ratio = 46:30) received allogenic hematopoietic stem cell transplantation (allo-HSCT). In total, 29 patients received HSCT from either a matched-related donor or a mismatched-related donor, 32 patients received an unrelated donor, and 15 patients received umbilical cord blood...
June 19, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29923123/impact-of-hospital-length-of-stay-on-the-risk-of-readmission-and-overall-survival-after-allogeneic-stem-cell-transplantation
#2
Aika Seto, Yoshiko Atsuta, Naomi Kawashima, Yukiyasu Ozawa, Koichi Miyamura, Hitoshi Kiyoi
Patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) are at high risk of readmission for complications. We sought to examine the association between HSCT hospital length of stay and the incidence of readmission and survival after discharge. We retrospectively reviewed the cases of 230 allo-HSCT recipients. The cumulative incidence of readmission with non-relapse transplant-related complications (including infections; acute and chronic GVHD; liver, lung, renal, or neurological complications; and haematological abnormalities) 2 years after the first discharge was 49...
June 19, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/29920784/eculizumab-for-transplant-associated-thrombotic-microangiopathy-in-adult-allogeneic-stem-cell-transplant-recipients
#3
Joslyn Rudoni, Anna Jan, Chitra Hosing, Fleur Aung, Jason Yeh
OBJECTIVE: To evaluate response rates and survival in adults with transplant-associated thrombotic microangiopathy (TA-TMA) after allogeneic hematopoietic stem cell transplantation (HSCT) who were treated with eculizumab (ECU). METHODS: Patients were identified retrospectively and data collected through HSCT and pharmacy databases. RESULTS: Ten patients with TA-TMA after allogeneic HSCT were treated with ECU between 2013 and 2016. TA-TMA was diagnosed at a median of 93 days post-HSCT...
June 19, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29915589/immunoglobulin-g-fragment-crystallizable-glycosylation-after-hematopoietic-stem-cell-transplantation-is-dissimilar-to-donor-profiles
#4
Noortje de Haan, Maarten J D van Tol, Gertjan J Driessen, Manfred Wuhrer, Arjan C Lankester
Immunoglobulin G (IgG) fragment crystallizable (Fc) N -glycosylation has a large influence on the affinity of the antibody for binding to Fcγ-receptors (FcγRs) and C1q protein, thereby influencing immune effector functions. IgG Fc glycosylation is known to be partly regulated by genetics and partly by stimuli in the microenvironment of the B cell. Following allogeneic hematopoietic stem cell transplantation (HSCT), and in the presence of (almost) complete donor chimerism, IgG is expected to be produced by, and glycosylated in, B cells of donor origin...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29910804/targeting-inflammatory-t-helper-cells-via-retinoic-acid-related-orphan-receptor-gamma-t-is-ineffective-to-prevent-allo-response-driven-colitis
#5
Vera Buchele, Benjamin Abendroth, Maike Büttner-Herold, Tina Vogler, Johanna Rothamer, Sakhila Ghimire, Evelyn Ullrich, Ernst Holler, Markus F Neurath, Kai Hildner
Intestinal graft-versus-host disease (GvHD) is a life-threatening, inflammatory donor T cell-mediated complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the light of the reported efficacy of interleukin-23 (IL-23)-blockade to mitigate syngeneic intestinal inflammation in inflammatory bowel disease patients, targeting IL-23 and thereby interleukin-17a (IL-17a) producing T helper (Th17) cells as the T cell subset assumed to be mostly regulated by IL-23, has emerged as a putatively general concept to harness immune-mediated mucosal inflammation irrespective of the underlying trigger...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29910468/enhanced-expressions-of-fhl2-and-iaspp-predict-poor-prognosis-in-acute-myeloid-leukemia
#6
Zhiheng Cheng, Yifeng Dai, Yifan Pang, Yang Jiao, Hongmian Zhao, Zhihui Zhang, Tong Qin, Ning Hu, Yijie Zhang, Xiaoyan Ke, Yang Chen, Depei Wu, Jinlong Shi, Lin Fu
iASPP is a negative regulator of the apoptotic function of p53, and it can enhance the ability of hematopoietic stem cells to self-renew and resist chemo- and radiation therapy. Recent study showed that iASPP could impact the proliferation and apoptosis of leukemia cells by interacting with FHL2. However, whether they have prognostic significance in acute myeloid leukemia (AML) is unknown. Eighty-four AML patients with FHL2 and iASPP expression data from The Cancer Genome Atlas database were enrolled in the study...
June 18, 2018: Cancer Gene Therapy
https://www.readbyqxmd.com/read/29909153/gastrointestinal-graft-versus-host-disease-is-a-risk-factor-for-post-engraftment-blood-stream-infection-in-allogeneic-hematopoietic-stem-cell-transplant-recipients
#7
Yasuo Mori, Goichi Yoshimoto, Ruriko Nishida, Takeshi Sugio, Kohta Miyawaki, Takahiro Shima, Yoji Nagasaki, Noriko Miyake, Yukiko Harada, Yuya Kunisaki, Kenjiro Kamezaki, Akihiko Numata, Koji Kato, Motoaki Shiratsuchi, Takahiro Maeda, Katsuto Takenaka, Hiromi Iwasaki, Nobuyuki Shimono, Koichi Akashi, Toshihiro Miyamoto
Bloodstream infection (BSI) is a well-known cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Here, we conducted a retrospective study to assess the morbidity, etiology, risk factors, and outcomes of BSI in the post-engraftment period (PE-BSI) following allo-HSCT. Forty-three out of 316 patients (13.6%) developed 57 PE-BSI episodes, in which 62 pathogens were isolated: gram-positive bacteria, gram-negative bacteria, and fungi, respectively, accounted for 54...
June 14, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29909151/hematogones-predict-better-outcome-in-allogeneic-hematopoietic-stem-cell-transplantation-irrespective-of-graft-sources
#8
Takashi Ishio, Junichi Sugita, Takahiro Tateno, Daisuke Hidaka, Eiko Hayase, Souichi Shiratori, Kohei Okada, Hideki Goto, Masahiro Onozawa, Masao Nakagawa, Daigo Hashimoto, Kaoru Kahata, Katsuya Fujimoto, Tomoyuki Endo, Takeshi Kondo, Takanori Teshima
Benign precursors of B lymphocytes, termed hematogones, are observed in the regenerative state of hematopoiesis following chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT). Previous studies have demonstrated that expansion of hematogones correlates with better clinical outcomes after allo-HSCT. We retrospectively analyzed the association between hematogones and clinical outcomes in 309 consecutive patients undergone allo-HSCT, which was the largest population-based cohort reported so far...
June 14, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29908230/additional-cytogenetic-abnormalities-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-on-allogeneic-stem-cell-transplantation-in-the-tyrosine-kinase-inhibitor-era
#9
Yu Akahoshi, Shuichi Mizuta, Hiroaki Shimizu, Naoyuki Uchida, Takahiro Fukuda, Heiwa Kanamori, Makoto Onizuka, Yukiyasu Ozawa, Kazuteru Ohashi, Shuichi Ohta, Tetsuya Eto, Junji Tanaka, Yoshiko Atsuta, Shinichi Kako
Cytogenetic abnormalities are well-known and powerful independent prognostic factor for various hematological disorders. Although the combination of chemotherapy with tyrosine kinase inhibitor (TKI) is now considered the standard of care in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, little is known about the impact of additional cytogenetic abnormalities (ACAs). Therefore, we retrospectively evaluated 1375 adult patients who underwent their first allogeneic hematopoietic stem cell transplantation in the TKI era...
June 13, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29905054/-research-of-acellular-xenogeneic-nerve-combined-with-adipose-derived-stem-cells-and-platelet-rich-plasma-in-repair-of-rabbit-facial-nerve-injury
#10
Yanna Sun, Rongming Zhang, Xu Mao, Mengshu Zhang
Objective: To investigate the early effects of acellular xenogeneic nerve combined with adipose-derived stem cells (ADSCs) and platelet rich plasma (PRP) in repairing facial nerve injury in rabbits. Methods: The bilateral sciatic nerves of 15 3-month-old male Sprague-Dawley rats were harvested and decellularized as xenografts. The allogeneic ADSCs were extracted from the neck and back fat pad of healthy adult New Zealand rabbits with a method of digestion by collagenase type Ⅰ and the autologous PRP was prepared by two step centrifugation...
June 1, 2018: Chinese Journal of Reparative and Reconstructive Surgery
https://www.readbyqxmd.com/read/29904127/strategies-to-enhance-the-graft-versus-tumour-effect-after-allogeneic-haematopoietic-stem-cell-transplantation
#11
Eric Wong, Joanne E Davis, Andrew Grigg, Jeff Szer, David Ritchie
Relapse of haematological malignancies after allogeneic haematopoietic stem cell transplant is a major cause of mortality. The immunological mechanisms that may lead to disease relapse may include immunological immaturity prior to reconstitution of the allogeneic immune system, tumour antigen downregulation or promotion of T-cell exhaustion by interactions with the tumour microenvironment. Current therapeutic strategies for post-transplant relapse are limited in their efficacy and alternative approaches are required...
June 14, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29904089/mutational-spectrum-and-prognostic-stratification-of-intermediate-risk-acute-myeloid-leukemia
#12
Sun Wu, Yifeng Dai, Yuan Zhang, Xiufeng Wang, Lihua Wang, Dong Ma, Lingxiu Zhang, Yifan Pang, Yang Jiao, Mingshan Niu, Kailin Xu, Xiaoyan Ke, Jinlong Shi, Zhiheng Cheng, Lin Fu
The mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia (IR-AML), which accounts for a substantial number of AML, are unclear. In order to explore the prognostic significance of the mutational spectrum in IR-AML, 106 IR-AML patients were collected from The Cancer Genome Atlas database. Sixty-two patients underwent chemotherapy-only, forty-four proceeded to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Fifty-five patients had more than five recurrent genetic mutations...
June 15, 2018: Cancer Gene Therapy
https://www.readbyqxmd.com/read/29903894/novel-approaches-to-acute-myeloid-leukemia-immunotherapy
#13
Ofrat Beyar-Katz, Saar Gill
Acute myeloid leukemia (AML) is a rapidly progressive, poor-prognosis malignancy arising from hematopoietic stem/progenitor cells. The long history of successful use of allogeneic hematopoietic cell transplantation (alloHCT) in AML indicates that this disease is immunoresponsive, leading to optimism that novel immunotherapies such as bispecific antibodies, chimeric antigen receptor T cells, and immune checkpoint inhibitors will generate meaningful disease control. However, emerging data on the immunoevasive tactics employed by AML blasts at diagnosis and at relapse indicate that optimism must be tempered by an understanding of this essential paradox...
June 14, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29903762/the-egvhd-app-has-the-potential-to-improve-the-accuracy-of-graft-versus-host-disease-assessment-a-multicenter-randomized-controlled-trial
#14
Helene M Schoemans, Kathy Goris, Raf Van Durm, Steffen Fieuws, Sabina De Geest, Steven Z Pavletic, Annie Im, Daniel Wolff, Stephanie J Lee, Hildegard Greinix, Rafael F Duarte, Xavier Poiré, Dominik Selleslag, Philippe Lewalle, Tessa Kerre, Carlos Graux, Frédéric Baron, Johan A Maertens, Fabienne Dobbels
Graft-versus-host disease assessment has been shown to be a challenge for healthcare professionals, leading to the development of the eGVHD App (www.uzleuven.be/egvhd). In this study, we formally evaluated the accuracy of using the App compared to traditional assessment methods to assess graft-versus-host disease. Our national multicenter randomized controlled trial involved seven Belgian transplantation centers and 78 healthcare professionals selected using a two-stage convenience sampling approach between January and April 2017...
June 14, 2018: Haematologica
https://www.readbyqxmd.com/read/29903026/serum-ifn-%C3%AE-levels-predict-the-therapeutic-effect-of-mesenchymal-stem-cell-transplantation-in-active-rheumatoid-arthritis
#15
Yi Yang, Xiao He, Rongseng Zhao, Wei Guo, Ming Zhu, Wei Xing, Dongpo Jiang, Chongyang Liu, Xiang Xu
BACKGROUND: To explore the mechanism of the different clinical efficacies of mesenchymal stem cell transplantation (MSCT) and identify a possible serum biomarker for predicting the therapeutic effect of MSCT in rheumatoid arthritis (RA) patients. METHODS: A total of 105 patients with persistently active RA and poor responses to traditional medication were randomly divided into MSCT and control groups. Outcomes were evaluated according to the 28-joint Disease Activity Score and Health Assessment Questionnaire, serological indicators, regulatory T cell (Treg) to T helper 17 (Th17) cell ratio, and inflammatory cytokine levels...
June 15, 2018: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29901213/pbpk-modeling-strategy-for-predicting-complex-drug-interactions-of-letermovir-as-a-perpetrator-in-support-of-product-labeling
#16
Ying-Hong Wang, Dapeng Chen, Georgy Hartmann, Carolyn R Cho, Karsten Menzel
Letermovir is a human cytomegalovirus (CMV) terminase inhibitor for the prophylaxis of CMV infection in allogeneic hematopoietic stem-cell transplant (HSCT) recipients. In vitro, letermovir is a time-dependent inhibitor and an inducer of cytochrome P450 (CYP)3A, and an inhibitor of CYP2C8 and organic anion transporting polypeptide (OATP)1B. A stepwise approach was taken to qualify the interaction model of an existing letermovir physiologically-based pharmacokinetic (PBPK) model to predict letermovir interactions with CYP3A and OATP1B...
June 14, 2018: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29899574/pre-engraftment-cytomegalovirus-dnaemia-in-allogeneic-hematopoietic-stem-cell-transplant-recipients-incidence-risk-factors-and-clinical-outcomes
#17
Carlos Solano, Estela Giménez, Eliseo Albert, Eva María Mateo, Montserrat Gómez, Rosa Goterris, Ariadna Pérez, Paula Amat, Juan Carlos Hernández-Boluda, Marc Poch, José Luis Piñana, David Navarro
To gauge the risk of delaying initiation of prophylaxis with letermovir from the time of donor infusion to prevent CMV infection in allo-HSCT recipients we investigated the clinical outcomes of CMV DNAemia episodes occurring before engraftment, and compared to that of episodes developing after engraftment (up to day +365). A total of 197 consecutive adult patients were included. Plasma CMV DNA load was monitored by real-time PCR assays [limit of detection: 31 IU/ml]. A total of 150 out of 197 patients had CMV DNAemia (cumulative incidence of 77%; 95% CI, 73-81%), and 38 out of the 197 patients developed it before engraftment (cumulative incidence, 19%; 95% CI, 10-30...
June 13, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29899572/hematopoietic-stem-cell-transplantation-for-isolated-extramedullary-relapse-of-acute-lymphoblastic-leukemia-in-children
#18
Maria Gabelli, Marco Zecca, Chiara Messina, Elisa Carraro, Barbara Buldini, Attilio Maria Rovelli, Franca Fagioli, Alice Bertaina, Edoardo Lanino, Claudio Favre, Marco Rabusin, Arcangelo Prete, Mimmo Ripaldi, Walter Barberi, Fulvio Porta, Maurizio Caniglia, Stella Santarone, Paolo D'Angelo, Giuseppe Basso, Franco Locatelli
Relapse of acute lymphoblastic leukemia (ALL) may occur in extramedullary sites, mainly central nervous system (CNS) and testis. Optimal post-remissional treatment for isolated extramedullary relapse (IEMR) is still controversial. We collected data of children treated with hematopoietic stem cell transplantation (HSCT) for ALL IEMR from 1990 to 2015 in Italy. Among 281 patients, 167 had a relapse confined to CNS, 73 to testis, 14 to mediastinum, and 27 to other organs. Ninety-seven patients underwent autologous HSCT, 79 received allogeneic HSCT from a matched family donor, 75 from a matched unrelated donor, and 30 from an HLA-haploidentical donor...
June 13, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29899571/the-safety-and-efficacy-of-clofarabine-in-combination-with-high-dose-cytarabine-and-total-body-irradiation-myeloablative-conditioning-and-allogeneic-stem-cell-transplantation-in-children-adolescents-and-young-adults-caya-with-poor-risk-acute-leukemia
#19
Jessica Hochberg, Stacey Zahler, Mark B Geyer, Nan Chen, Jennifer Krajewski, Lauren Harrison, Olga Militano, M Fevzi Ozkaynak, Alexandra C Cheerva, Julie Talano, Theodore B Moore, Alfred P Gillio, Mark C Walters, Lee Ann Baxter-Lowe, Carl Hamby, Mitchell S Cairo
Acute leukemias in children with CR3, refractory relapse, or induction failure (IF) have a poor prognosis. Clofarabine has single agent activity in relapsed leukemia and synergy with cytarabine. We sought to determine the safety and overall survival in a Phase I/II trial of conditioning with clofarabine (doses 40 - 52 mg/m2 ), cytarabine 1000 mg/m2 , and 1200 cGy TBI followed by alloSCT in children, adolescents, and young adults with poor-risk leukemia. Thirty-seven patients; Age 12 years (1-22 years); ALL/AML: 34:3 (18 IF, 10 CR3, 13 refractory relapse); 15 related, 22 unrelated donors...
June 13, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29899549/colonic-graft-vs-host-disease-in-autologous-versus-allogeneic-transplant-patients-earlier-onset-more-apoptosis-and-lack-of-regulatory-t-cell-attenuation
#20
Christopher P Hartley, Luis F Carrillo-Polanco, Daniel J Rowan, Catherine E Hagen
Histologic characterization of graft-vs.-host disease in autologous stem cell transplant patients has been limited. The aims of this study were to characterize colonic graft-vs.-host disease in autologous stem cell transplant patients and compare to a control group of allogeneic stem cell transplant patients, to determine whether graft-vs.-host disease can be diagnosed < 21 days post transplantation in autologous stem cell transplant recipients, and to quantify colonic T-cell populations in autologous stem cell transplant patients...
June 13, 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
keyword
keyword
52922
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"